Leishmaniasis News and Research

RSS

Leishmaniasis is a parasitic disease transmitted by the bite of infected sand flies. It is found in nearly 88 countries, from rain forests in Central and South America to deserts in the Middle East and west Asia. Some cases of the disease have also appeared in Mexico and Texas.

Leishmaniasis takes several different forms, including the most common cutaneous leishmaniasis, which causes skin sores, and the more severe visceral leishmaniasis, which affects internal organs such as the spleen, liver, and bone marrow. The World Health Organization (WHO) estimates that there are 1.5 million new cases of cutaneous leishmaniasis and 500,000 new cases of visceral leishmaniasis in the world each year.

Grand Challenges Canada announces 15 grants to support rising stars in global health

Grand Challenges Canada today announced 15 grants valued in total at more than $1.5 million awarded to some of Canada's most creative innovators from across the country in support of their work to improve global health conditions.

10 Feb 2012

Researchers identify fexinidazole as potential new therapy for visceral leishmaniasis

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis.

3 Feb 2012

Major effort to tackle neglected tropical diseases

Thirteen drug companies, the governments of the United States, Britain and the United Arab Emirates, the World Bank, the Bill and Melinda Gates Foundation, the Lions Club and other smaller charitable organizations on Monday announced a joint effort to tackle 10 neglected tropical diseases in a coordinated fashion.

31 Jan 2012

Abbott, DNDi partner to research on new treatments for NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

31 Jan 2012

DWH signs collaboration agreement with CPDD

Developing World Health (DWH), a leading medical charity based in Stirlingshire, Scotland and committed to developing effective treatments for neglected tropical diseases, has signed a collaboration agreement with the internationally respected Consortium for Parasitic Drug Development (CPDD), based at The University of North Carolina at Chapel Hill.

27 Jan 2012

Infectious disease-fighting drugs could be designed to block pathogen's entry into cells

New research shows that infectious disease-fighting drugs could be designed to block a pathogen's entry into cells rather than to kill the bug itself.

11 Jan 2012

Leishmania parasite develops combined resistance against drug, human immune system

Scientists of the Institute of Tropical Medicine (ITG) discovered a parasite that not only had developed resistance against a common medicine, but at the same time had become better in withstanding the human immune system.

22 Dec 2011

Examining visceral leishmaniasis/HIV co-infection in East Africa

In this post in the Global Network for Neglected Tropical Diseases' (NTDs) "End the Neglect" blog, Julien Potet, NTD policy adviser at Medecins Sans Frontieres' Campaign for Access to Essential Medicines, examines the treatment of visceral leishmaniasis among people living with HIV in East Africa.

9 Dec 2011

Gilead Sciences to donate $8M in visceral leishmaniasis drug to WHO

Gilead Sciences, Inc. "will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar," a Gilead press release states, adding, "If sold at Gilead's no-profit access price, today's donation would cost more than $8 million."

9 Dec 2011

Cayetano Heredia, UT Southwestern sign five-year affiliation agreement

UT Southwestern Medical Center and the Universidad Peruana Cayetano Heredia in Peru have signed a five-year affiliation agreement that establishes an exchange program for medical students and related educational opportunities.

6 Dec 2011

Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease

Today, at the occasion of the 4th DNDi Partners' Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi).

3 Dec 2011

DNDi highlights lack of healthcare coverage for children with HIV/AIDS

Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day.

2 Dec 2011

New creative uses of DNA 'barcoding'

The newfound scientific power to quickly "fingerprint" species via DNA is being deployed to unmask quack herbal medicines, reveal types of ancient Arctic life frozen in permafrost, expose what eats what in nature, and halt agricultural and forestry pests at borders, among other applications across a wide array of public interests.

28 Nov 2011

Four-year project aims to boost kala-azar elimination efforts in India, Bangladesh

In this post in the Global Health Technologies Coalition's "Breakthroughs" blog, Elena Pantjushenko, a communications associate for GHTC member OneWorld Health (OWH), profiles a "comprehensive four-year project to boost kala-azar (leishmaniasis) elimination strategies in India and Bangladesh, where the concentration of disease burden is among the world's highest."

24 Nov 2011

OWH to participate in major kala-azar elimination project

OneWorld Health (OWH) announced that it will participate in a major consortium project aimed to boost strategies for control and eventual elimination of visceral leishmaniasis (VL or kala-azar) in India and Bangladesh, where the disease burden is among the world's highest.

10 Nov 2011

Four-year kala azar treatment study launched in India, Bangladesh

"A four-year test of drugs to treat a widespread parasitic disease called kala azar was announced on Monday by the governments of India and Bangladesh, Doctors Without Borders, the Drugs for Neglected Diseases Initiative [DNDi] and other groups," the New York Times reports.

9 Nov 2011

Largest-ever implementation study on kala-azar in Asia

A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world's highest.

7 Nov 2011

Study outlines evolution of malaria, leishmaniasis and trypanosomiasis

One of the most comprehensive analyses yet done of the ancient history of insect-borne disease concludes for the first time that malaria is not only native to the New World, but it has been present long before humans existed and has evolved through birds and monkeys.

3 Nov 2011

Scientists identify nicotinamidase enzyme as new drug target for Leishmaniasis

IRD scientist and their research partners recently identified the key role of nicotinamidase, an enzyme in the parasite Leishmania, essential for its survival but which does not exist in humans. The pathogen is incapable of developing in mammals In the absence of this enzyme. Specific targeting of this enzyme could lead to more effective ways of controlling this neglected tropical disease.

29 Oct 2011

Scientists discover Leishmania parasite with juggling chromosomes

Scientists found a deadly parasite with some of its chromosomes in duplicate, others in triplicate, while still others are present four or even five times. Moreover, the copy number varies between individuals. Such a bizarre occurrence has never before been found in nature, in any organism. As a rule, chromosomes should come in couples. The scientists, from the Institute of Tropical Medicine (ITG) and the Wellcome Trust Sanger Institute, made the striking discovery while deciphering the genetic code of a series of Leishmania-parasites.

29 Oct 2011